Immunocellular Thera (IMUC) 0.57 $IMUC
ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial
PR Newswire - Thu Mar 19, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). This agreement with PharmaCell, a leading European contract manufacturing organization focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015.
IMUC: 0.57 (-0.01)
ImmunoCellular's (IMUC) CEO Andrew Gengos on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 8:39PM CDT
IMUC: 0.57 (-0.01)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 124.76 (-1.64), ZIOP: 13.89 (-0.11), PFE: 34.25 (+0.10), XON: 46.11 (-1.26), AMGN: 170.10 (+0.99), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), CELG: 128.50 (+3.17), JNJ: 102.40 (+0.71), BLCM: 25.19 (-0.71), KITE: 71.89 (-1.62), JUNO: 61.53 (+1.85), NVS: 101.68 (+1.81)
ImmunoCellular Therapeutics FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 6:54AM CDT
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics beats by $0.02
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:04PM CDT
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Mon Mar 09, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced financial results for the fourth quarter and year ended December 31, 2014.
IMUC: 0.57 (-0.01)
Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.97 (-0.25), OMED: 28.00 (+0.92), BIOA: 9.00 (+0.03), SUPN: 11.35 (-0.11), CTIC: 1.93 (unch), ALXA: 2.13 (-0.04), DSCI: 8.86 (-0.11), ANTH: 4.34 (-0.08), CYTX: 1.19 (-0.03), KYTH: 48.22 (+0.21), ANAC: 54.24 (-1.88), ATHX: 3.20 (+0.03), CRMD: 7.75 (-0.18), ACRX: 4.15 (-0.09), TROV: 7.04 (-0.35), ZGNX: 1.38 (+0.02), PETX: 18.74 (-0.30), RPRX: 8.98 (-0.26), IMUC: 0.57 (-0.01), PGNX: 6.06 (-0.45), SNTA: 2.48 (+0.07), BLCM: 25.19 (-0.71), TXMD: 6.40 (+0.15), OGXI: 2.30 (-0.16), AST: 7.88 (-0.40), PLX: 1.76 (-0.03), ATRS: 2.67 (-0.02)
ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th
PR Newswire - Tue Mar 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 27th Annual ROTH Conference on Tuesday, March 10, 2014 at 8:30 am PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA.
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015
PR Newswire - Mon Mar 02, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it plans to report financial results for the year ended December 31, 2014 on March 9, 2015. The Company also plans to hold a business update conference call and webcast on Thursday, March 12, 2015, at 5:00 pm ET. The call will be hosted by Andrew Gengos, President and CEO.
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Strengthens Executive Management Team with Appointment of Dr. Steven Swanson to Lead Stem-to-T-Cell Program
PR Newswire - Wed Feb 18, 3:05PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced the appointment of Steven J. Swanson, PhD, as Senior Vice President, Research. Dr. Swanson will lead the Company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic. Dr. Swanson has more than 25 years of pharmaceutical and biotechnology experience, with a specialty in immunology, and has been an industry leader in advancing global standards for immunogenicity assessment.
IMUC: 0.57 (-0.01)
Hot Stock: ImmunoCellular Therapeutics, Shares Drop 12.9% (IMUC)
Comtex SmarTrend(R) - Thu Feb 12, 10:39AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 12.9% to $0.58 on 6.7x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.8 million shares, vs. average volume of 270,000 shares per day. The stock has underperformed the Dow (-12.9% to the Dow's 0.3%) and underperformed the S&P 500 (-12.9% to the S&P's 0.6%) during today's trading.
IMUC: 0.57 (-0.01)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 9.65 (-0.28), OCAT: 6.10 (-0.05), VCEL: 3.74 (+0.15), PSTI: 2.80 (-0.05), NBS: 3.17 (-0.13), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), KITE: 71.89 (-1.62), BAX: 68.18 (+0.20), ONCE: 69.95 (-4.22), JUNO: 61.53 (+1.85), ATHX: 3.20 (+0.03), CUR: 2.42 (+0.14)
ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
PR Newswire - Thu Feb 12, 7:06AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price to the public of $0.60 per share, and warrants to purchase up to an aggregate of 18,655,000 shares of its common stock. The net offering proceeds to ImmunoCellular from this offering are expected to be approximately $14.6 million, after deducting the underwriting discount and estimated offering expenses payable by ImmunoCellular, but excluding the exercise of any warrants.
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015
PR Newswire - Wed Jan 28, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.
IMUC: 0.57 (-0.01)
What's To Like About CytRx's Brain Cancer Data?
Investing Healthcare - at Seeking Alpha - Tue Jan 20, 2:37AM CST
CYTR: 3.35 (+0.04), IMUC: 0.57 (-0.01)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 58.58 (+0.37), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), HPTX: 40.49 (+0.85)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 166.49 (+0.83), NWBO: 7.63 (-0.19), MRK: 58.58 (+0.37), IMUC: 0.57 (-0.01)
Stock to Watch: ImmunoCellular Therapeutics Up 13.7% (IMUC)
Comtex SmarTrend(R) - Mon Dec 29, 12:39PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 13.7% to $0.76 on 1.0x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 675,000 shares, vs. average volume of 653,000 shares per day. The stock has outperformed the Dow (13.7% to the Dow's -0.0%) and outperformed the S&P 500 (13.7% to the S&P's 0.2%) during today's trading.
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
PR Newswire - Wed Dec 17, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens that are commonly expressed on glioblastoma. The claims of US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating neural cancer by administering a dendritic cell composition comprising peptide epitopes of the six tumor antigens of ICT-107. The claims specifically cover administration of the recited dendritic cell composition to a patient suffering from glioma, which is inclusive of glioblastoma multiforme.
IMUC: 0.57 (-0.01)
Stock to Watch: ImmunoCellular Therapeutics Down 7.2% (IMUC)
Comtex SmarTrend(R) - Thu Dec 04, 12:41PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 7.2% to $0.93 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 480,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.0%) and underperformed the S&P 500 (-7.2% to the S&P's 0.0%) during today's trading.
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial
PR Newswire - Thu Mar 19, 5:00AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). This agreement with PharmaCell, a leading European contract manufacturing organization focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015. IMUC: 0.57 (-0.01)
ImmunoCellular's (IMUC) CEO Andrew Gengos on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 8:39PM CDT
IMUC: 0.57 (-0.01)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 124.76 (-1.64), ZIOP: 13.89 (-0.11), PFE: 34.25 (+0.10), XON: 46.11 (-1.26), AMGN: 170.10 (+0.99), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), CELG: 128.50 (+3.17), JNJ: 102.40 (+0.71), BLCM: 25.19 (-0.71), KITE: 71.89 (-1.62), JUNO: 61.53 (+1.85), NVS: 101.68 (+1.81)
ImmunoCellular Therapeutics FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 6:54AM CDT
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics beats by $0.02
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:04PM CDT
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Mon Mar 09, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the fourth quarter and year ended December 31, 2014. IMUC: 0.57 (-0.01)
Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.97 (-0.25), OMED: 28.00 (+0.92), BIOA: 9.00 (+0.03), SUPN: 11.35 (-0.11), CTIC: 1.93 (unch), ALXA: 2.13 (-0.04), DSCI: 8.86 (-0.11), ANTH: 4.34 (-0.08), CYTX: 1.19 (-0.03), KYTH: 48.22 (+0.21), ANAC: 54.24 (-1.88), ATHX: 3.20 (+0.03), CRMD: 7.75 (-0.18), ACRX: 4.15 (-0.09), TROV: 7.04 (-0.35), ZGNX: 1.38 (+0.02), PETX: 18.74 (-0.30), RPRX: 8.98 (-0.26), IMUC: 0.57 (-0.01), PGNX: 6.06 (-0.45), SNTA: 2.48 (+0.07), BLCM: 25.19 (-0.71), TXMD: 6.40 (+0.15), OGXI: 2.30 (-0.16), AST: 7.88 (-0.40), PLX: 1.76 (-0.03), ATRS: 2.67 (-0.02)
ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th
PR Newswire - Tue Mar 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 27th Annual ROTH Conference on Tuesday, March 10, 2014 at 8:30 am PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA. IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015
PR Newswire - Mon Mar 02, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report financial results for the year ended December 31, 2014 on March 9, 2015. The Company also plans to hold a business update conference call and webcast on Thursday, March 12, 2015, at 5:00 pm ET. The call will be hosted by Andrew Gengos, President and CEO. IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Strengthens Executive Management Team with Appointment of Dr. Steven Swanson to Lead Stem-to-T-Cell Program
PR Newswire - Wed Feb 18, 3:05PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced the appointment of Steven J. Swanson, PhD, as Senior Vice President, Research. Dr. Swanson will lead the Company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic. Dr. Swanson has more than 25 years of pharmaceutical and biotechnology experience, with a specialty in immunology, and has been an industry leader in advancing global standards for immunogenicity assessment. IMUC: 0.57 (-0.01)
Hot Stock: ImmunoCellular Therapeutics, Shares Drop 12.9% (IMUC)
Comtex SmarTrend(R) - Thu Feb 12, 10:39AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 12.9% to $0.58 on 6.7x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.8 million shares, vs. average volume of 270,000 shares per day. The stock has underperformed the Dow (-12.9% to the Dow's 0.3%) and underperformed the S&P 500 (-12.9% to the S&P's 0.6%) during today's trading.
IMUC: 0.57 (-0.01)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 9.65 (-0.28), OCAT: 6.10 (-0.05), VCEL: 3.74 (+0.15), PSTI: 2.80 (-0.05), NBS: 3.17 (-0.13), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), KITE: 71.89 (-1.62), BAX: 68.18 (+0.20), ONCE: 69.95 (-4.22), JUNO: 61.53 (+1.85), ATHX: 3.20 (+0.03), CUR: 2.42 (+0.14)
ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
PR Newswire - Thu Feb 12, 7:06AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price to the public of $0.60 per share, and warrants to purchase up to an aggregate of 18,655,000 shares of its common stock. The net offering proceeds to ImmunoCellular from this offering are expected to be approximately $14.6 million, after deducting the underwriting discount and estimated offering expenses payable by ImmunoCellular, but excluding the exercise of any warrants. IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015
PR Newswire - Wed Jan 28, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City. IMUC: 0.57 (-0.01)
What's To Like About CytRx's Brain Cancer Data?
Investing Healthcare - at Seeking Alpha - Tue Jan 20, 2:37AM CST
CYTR: 3.35 (+0.04), IMUC: 0.57 (-0.01)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 58.58 (+0.37), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), HPTX: 40.49 (+0.85)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 166.49 (+0.83), NWBO: 7.63 (-0.19), MRK: 58.58 (+0.37), IMUC: 0.57 (-0.01)
Stock to Watch: ImmunoCellular Therapeutics Up 13.7% (IMUC)
Comtex SmarTrend(R) - Mon Dec 29, 12:39PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 13.7% to $0.76 on 1.0x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 675,000 shares, vs. average volume of 653,000 shares per day. The stock has outperformed the Dow (13.7% to the Dow's -0.0%) and outperformed the S&P 500 (13.7% to the S&P's 0.2%) during today's trading.
IMUC: 0.57 (-0.01)
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
PR Newswire - Wed Dec 17, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens that are commonly expressed on glioblastoma. The claims of US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating neural cancer by administering a dendritic cell composition comprising peptide epitopes of the six tumor antigens of ICT-107. The claims specifically cover administration of the recited dendritic cell composition to a patient suffering from glioma, which is inclusive of glioblastoma multiforme. IMUC: 0.57 (-0.01)
Stock to Watch: ImmunoCellular Therapeutics Down 7.2% (IMUC)
Comtex SmarTrend(R) - Thu Dec 04, 12:41PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 7.2% to $0.93 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 480,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.0%) and underperformed the S&P 500 (-7.2% to the S&P's 0.0%) during today's trading.
IMUC: 0.57 (-0.01)
